Daniel Fong

Dr. Daniel Fong

The University of Hong Kong, Hong Kong, China
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2004 in JAMA
Verified
Journal Article
Open access
PDF file
BWBenjamin Chun-Yu Wong
Benjamin Chun-Yu Wong
SLShiu Kum Lam
Shiu Kum Lam
WWWai Man Wong
Wai Man Wong
JCJian Shun Chen
Jian Shun Chen
TZTing Ting Zheng
Ting Ting Zheng
FGfor the China Gastric Cancer Study Group
for the China Gastric Cancer Study Group
Research from JAMA — Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China — A Randomized Controlled Trial — ContextAlthough chronic Helicobacter pylori infection is associated with gastric cancer, the effect of H pylori treatment on prevention of gastric cancer development in chronic carriers is unknown.ObjectiveTo determine whether treatment of H pylori infection reduces the incidence of gastric cancer.Design, Setting, and ParticipantsProspective, randomized, placebo-controlled, population-based primary prevention study of 1630 healthy carriers of H pylori infection from Fujian Province, China, recruited in July 1994 and followed up until January 2002. A total of 988 participants did not have precancerous lesions (gastric atrophy, intestinal metaplasia, or gastric dysplasia) on study entry.InterventionPatients were randomly assigned to receive H pylori eradication treatment: a 2-week course of omeprazole, 20 mg, a combination product of amoxicillin and clavulanate potassium, 750 mg, and metronidazole, 400 mg, all twice daily (n = 817); or placebo (n = 813).Main Outcome MeasuresThe primary outcome measure was incidence of gastric cancer during follow-up, compared between H pylori eradication and placebo groups. The secondary outcome measure was incidence of gastric cancer in patients with or without precancerous lesions, compared between the 2 groups.ResultsAmong the 18 new cases of gastric cancers that developed, no overall reduction was observed in participants who received H pylori eradication treatment (n = 7) compared with those who did not (n = 11) (P = .33). In a subgroup of patients with no precancerous lesions on presentation, no patient developed gastric cancer during a follow-up of 7.5 years after H pylori eradication treatment compared with those who received placebo (0 vs 6; P = .02). Smoking (hazard ratio [HR], 6.2; 95% confidence interval [CI], 2.3-16.5; P<.001) and older age (HR, 1.10; 95% CI, 1.05-1.15; P<.001) were independent risk factors for the development of gastric cancer in this cohort.ConclusionsWe found that the incidence of gastric cancer development at the population level was similar between participants receiving H pylori eradication treatment and those receiving placebo during a period of 7.5 years in a high-risk region of China. In the subgroup of H pylori carriers without precancerous lesions, eradication of H pylori significantly decreased the development of gastric cancer. Further studies to investigate the role of H pylori eradication in participants with precancerous lesions are warranted.

30 January 2012 in BMJ
Verified
Journal Article
Open access
PDF file
Daniel FongDaniel Fong
Daniel Fong
JHJ. W. C. Ho
J. W. C. Ho
BHBryant Pui Hung Hui
Bryant Pui Hung Hui
ALAntoinette M Lee
Antoinette M Lee
DMDuncan J Macfarlane
Duncan J Macfarlane
KCK.K. Cheng
K.K. Cheng
Objective To systematically evaluate the effects of physical activity in adult patients after completion of main treatment related to cancer. Design Meta-analysis of randomised controlled trials with data extraction and quality assessment performed independently by two researchers. Data sources Pubmed, CINAHL, and Google Scholar from the earliest possible year to September 2011. References from meta-analyses and reviews. Study selection Randomised controlled trials that assessed the effects of physical activity in adults who had completed their main cancer treatment, except hormonal treatment. Results There were 34 randomised controlled trials, of which 22 (65%) focused on patients with breast cancer, and 48 outcomes in our meta-analysis. Twenty two studies assessed aerobic exercise, and four also included resistance or strength training. The median duration of physical activity was 13 weeks (range 3-60 weeks). Most control groups were considered sedentary or were assigned no exercise. Based on studies on patients with breast cancer, physical activity was associated with improvements in insulin-like growth factor-I, bench press, leg press, fatigue, depression, and quality of life. When we combined studies on different types of cancer, we found significant improvements in body mass index (BMI), body weight, peak oxygen consumption, peak power output, distance walked in six minutes, right handgrip strength, and quality of life. Sources of study heterogeneity included age, study quality, study size, and type and duration of physical activity. Publication bias did not alter our conclusions. Conclusions Physical activity has positive effects on physiology, body composition, physical functions, psychological outcomes, and quality of life in patients after treatment for breast cancer. When patients with cancer other than breast cancer were also included, physical activity was associated with reduced BMI and body weight, increased peak oxygen consumption and peak power output, and improved quality of life.

1 November 2007 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
ALAntoinette M. Lee
Antoinette M. Lee
SLSiu Keung Lam
Siu Keung Lam
SLStephanie Marie Sze Mun Lau
Stephanie Marie Sze Mun Lau
CCCatherine Shiu Yin Chong
Catherine Shiu Yin Chong
HCHang Wai Chui
Hang Wai Chui
Daniel FongDaniel Fong
Daniel Fong
To estimate the prevalence and course of antenatal anxiety and depression across different stages of pregnancy, risk factors at each stage, and the relationship between antenatal anxiety and depression and postpartum depression. A consecutive sample of 357 pregnant women in an antenatal clinic in a regional hospital was assessed longitudinally at four stages of pregnancy: first trimester, second trimester, third trimester, and 6 weeks postpartum. The antenatal questionnaire assessed anxiety and depression (using the Hospital Anxiety and Depression Scale) and demographic and psychosocial risk factors. The postpartum questionnaire assessed postpartum depression with the Edinburgh Postnatal Depression Scale. More than one half (54%) and more than one third (37.1%) of the women had antenatal anxiety and depressive symptoms, respectively, in at least one antenatal assessment. Anxiety was more prevalent than depression at all stages. A mixed-effects model showed that both conditions had a nonlinear changing course (P<.05 for both), with both being more prevalent and severe in the first and third trimesters. Risk factors were slightly different at different stages. Both antenatal anxiety (adjusted odds ratio [OR] 2.66, P=.004 in the first trimester; adjusted OR 3.65, P<.001 in the second trimester; adjusted OR 3.84, P<.001 in the third trimester) and depression (adjusted OR 4.16, P<.001 in the first trimester; adjusted OR 3.35, P=.001 in the second trimester; adjusted OR 2.67, P=.009 in the third trimester) increased the risk of postpartum depression. Antenatal anxiety and depression are prevalent and serious problems with changing courses. Continuous assessment over the course of pregnancy is warranted. Identifying and treating these problems is important in preventing postpartum depression. II.

1 January 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
MYMan-Fung Yuen
Man-Fung Yuen
YTYasuhito Tanaka
Yasuhito Tanaka
Daniel FongDaniel Fong
Daniel Fong
JFJames Fung
James Fung
DWDanny Ka-Ho Wong
Danny Ka-Ho Wong
Ching-Lung LaiChing-Lung Lai
Ching-Lung Lai

1 December 2003 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
GLGeorge K.K Lau
George K.K Lau
HYHarry H.Y Yiu
Harry H.Y Yiu
Daniel FongDaniel Fong
Daniel Fong
HCHoi-Ching Cheng
Hoi-Ching Cheng
WAWing-Yan Au
Wing-Yan Au
RLRaymond Liang
Raymond Liang

1 August 2005 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
CLCindy L.K. Lam
Cindy L.K. Lam
ETEileen Y.Y. Tse
Eileen Y.Y. Tse
BGBarbara Gandek
Barbara Gandek
Daniel FongDaniel Fong
Daniel Fong
To find out whether the SF-36 physical and mental health summary (PCS and MCS) scales are valid and equivalent in the Chinese population in Hong Kong (HK). The SF-36 data of a cross-sectional study on 2,410 Chinese adults randomly selected from the general population in HK were analyzed. The hypothesized two-factor structure of the physical and mental health summary scales (PCS and MCS) was replicated and the expected differences in scores between known morbidity groups were shown. The internal reliability coefficients of the PCS and MCS scales ranged from 0.85 to 0.87. The effect size differences between the U.S. standard and HK-specific PCS and MCS scores were mostly <0.5. The effect size differences in the standard PCS and MCS scores of specific groups between the U.S. and H.K. populations were all <0.5. The PCS and MCS scales were applicable to the Chinese population in HK. The high level of measurement equivalence of the scales between the U.S. and H.K. populations suggests that data pooling between the two populations could be possible. To our knowledge, this is the first study to show that the SF-36 summary scales are valid and equivalent in an Asian population.